Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

preview_player
Показать описание
The 2022 updates of international guidelines affect diagnosis, classification and management of HR-MDS and AML.

Get up-to-date on their impact on clinical practice with expert perspectives.

With Prof. Andrew Wei, Prof. Agnieszka Wierzbowska and Prof. Gert Ossenkoppele.

--------
This activity is supported by an independent medical education grant from Novartis and is provided by touchIME.
  1. Touch Medical Media
Рекомендации по теме
Higher-risk MDS and 0:33:29

Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

Understanding Higher Risk 1:13:29

Understanding Higher Risk MDS and Transtion to AML

Higher-risk MDS and 0:57:07

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

Understanding QoL (Quality 1:02:31

Understanding QoL (Quality of life) in High-Risk MDS & AML

Expert Video Report 0:06:53

Expert Video Report on Acute Myeloid Leukemia and high risk MDS from ASH 2020

Uma Borate: Evaluating 0:04:32

Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

MDS/AML Overlap and 0:09:29

MDS/AML Overlap and Novel Therapies with Dr. Naval Daver

Immunomodulation with pomalidomide 0:06:11

Immunomodulation with pomalidomide in AML and high-risk MDS

MDS - AML 0:50:26

MDS - AML - 2020 Spring Virtual Conference: When MDS becomes AML - for High-Risk MDS Patients

What Are My 1:16:58

What Are My Options with High Risk MDS AML

How is higher-risk 0:02:50

How is higher-risk MDS treated?

Differences and similarities 0:01:09

Differences and similarities between MDS and AML & how this can inform treatment decisions

Venetoclax in Higher-Risk 0:16:23

Venetoclax in Higher-Risk MDS/AML

Sabatolimab plus HMAs 0:04:47

Sabatolimab plus HMAs in high-/very high-risk MDS and ND-AML

Advances in Treating 1:00:20

Advances in Treating High Risk MDS and AML

High-Risk MDS/AML: Genomic-Driven 0:05:15

High-Risk MDS/AML: Genomic-Driven Approaches from ASH19 - Eytan Stein, MD

Dr. Sekeres on 0:01:20

Dr. Sekeres on the Need for Novel Combinations in Higher-Risk MDS/CMML and Low-Blast AML

MBG453 with hypomethylating 0:07:28

MBG453 with hypomethylating agents in AML and high-risk MDS

Managing Higher Risk 1:00:54

Managing Higher Risk MDL and AML

High Risk MDS 1:32:06

High Risk MDS Treatment Strategies

Low-Risk and High-Risk 0:14:08

Low-Risk and High-Risk MDS

Community Perspectives on 1:32:49

Community Perspectives on Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome

Treatments for MDS 0:06:13

Treatments for MDS and Secondary AML - Part 2, High-Risk

MPN Transformation to 0:20:12

MPN Transformation to MDS and AML: Risk factors, therapy and outcomes

Комментарии
Автор

Does it really matter as the treatments are mostly the same. I refuse to have a bone marrow aspiration. They are saying MDS but treatment seems the same. I would never consider a BMT so just treat as things come up. For now I have low white and platelets and reds are about to go below normal. I don’t see treatments very different

amybradley